Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
NEW YORK, March 07, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CTI BioPharma Corp. securities (NASDAQ:CTIC) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with CTI BioPharma’s September 24, 2015 Public Offering (the “offering”) and/or between March 4, 2014 through February 9, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for CTI BioPharma investors under the federal securities laws.
To join the CTI BioPharma class action, go to the firm’s website at http://rosenlegal.com/cases-837.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, the documents filed in connection with the offering contained materially false and misleading statements and omissions, including: (1) the detrimental effect on survival of pacritinib; (2) CTI BioPharma’s clinical trials demonstrated deaths associated with pacritinib usage; (3) CTI BioPharma’s new drug application for pacritinib would likely be withdrawn; (4) as such, CTI BioPharma’s future revenues were impaired; (5) CTI BioPharma lacked adequate internal controls; and (6) as a result, CTI BioPharma’s financial statements and Defendants’ statements about CTI Biopharma’s business, operations, and prospects, were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-837.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
